On the heels of the recall of Vioxx in September 2004, results of a study were issued to the American Heart Association on November 9, 2004 linking Bextra to heart attacks. Bextra was taken off the market on April 7, 2005.
The study, which consisted of approximately 6,000 patients taking part in 12 trials, found that the incidence of heart attacks and strokes among patients take Bextra was more than TWICE those given placebos.
According the Dr. Garret A. FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania, "The magnitude of the signal with Bextra is even higher than what we saw in Vioxx. This is a time bomb waiting to go off."
Bextra has also been linked, along with Vioxx and Celebrex to Stevens-Johnson Syndrome. Stevens-Johnson Syndrome is a rare inflammatory skin disorder that can be life-threatening. If you have suffered from Stevens-Johnson Syndrome as a result of taking Bextra, click here.
About Bextra
Bextra, also known as valdecoxib, was approved by the FDA on November 2001 and went to market in March 2002. Bextra is made by Pharmacia/Pfizer.
Bextra is prescribed for the relief of symptoms of:
- osteoarthritis (also known as "wear and tear" arthritis, a degenerative joint disease common in older people)
- adult rheumatoid arthritis (a severe form of arthritis which affects over 2 million people)
- primary dysmennorhea (severe menstrual cramping)
Bextra is taken once daily. It is classified as a COX-2 inhibitor, part of a group of non-steroidal anti-inflammatory medications (NSAIDs). COX-2 inhibitors block one of the enzymes which causes pain and inflammation; other similar drugs include Vioxx and Celebrex.
Note - Do not change medications without first consulting your doctor.